Genomic scarring score as a criterion for PARP inhibitor administration in early-stage NSCLC

被引：0

作者：

Klinakis, A. ^{[1
]}

Tsilingiri, K. ^{[1
]}

Chalari, A. ^{[1
]}

Voutsina, A. ^{[2
]}

Christopoulou, G. ^{[3
]}

Vatselas, G. ^{[4
]}

Potaris, K. ^{[5
]}

Vamvakaris, I. ^{[6
]}

Hatzidaki, D. ^{[7
]}

Zachou, G. ^{[8
]}

Georgoulias, V. ^{[7
]}

Konstantoulakis, P. ^{[3
]}

Kotsakis, A. ^{[9
]}

机构：

[1] Biomed Res Fdn Acad Athens BRFAA, Ctr Basic Res, Athens, Greece

[2] Natl Hellen Res Fdn, Inst Chem Biol, Athens, Greece

[3] Genotypos Sci Labs, Mol Genet, Athens, Greece

[4] Biomed Res Fdn Acad Athens BRFAA, Greek Genome Ctr, Athens, Greece

[5] SOTIRIA Gen Hosp Athens, Dept Thorac Surg, Athens, Greece

[6] Sotiria Thorac Dis Hosp Athens, Dept Pathol, Athens, Greece

[7] Hellen Oncol Res Grp, Athens, Greece

[8] Metropolitan Gen Hosp, Oncol, Cholargos, Greece

[9] Univ Thessaly, Med Oncol Dept, Larisa, Greece

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

基金：

欧盟地平线“2020”;

关键词：

D O I：

10.1016/j.annonc.2024.08.1292

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1233P

引用

页码：S791 / S791

页数：1

共 50 条

[21] Genomic characterization of early-stage asymptomatic lung cancers
Belloni, E.
Veronesi, G.
Micucci, C.
Javan, S.
Scanagatta, P.
Taliento, G.
Pelosi, G.
Pece, S.
Spaggiari, L.
Pelicci, P. G.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[22] Current status of immune checkpoint inhibition in early-stage NSCLC
Vansteenkiste, J.
Wauters, E.
Reymen, B.
Ackermann, C. J.
Peters, S.
De Ruysscher, D.
ANNALS OF ONCOLOGY, 2019, 30 (08) : 1244 - 1253
[23] Prognosticator of SBRT efficacy and toxicity in early-stage NSCLC patients
Walz, D.
Salome, P.
Sforazzini, F.
Kudak, A.
Dostal, M.
Regnery, S.
Schlamp, K.
Heussel, C. P.
Herth, F.
Thomas, M.
Hoerner-Rieber, J.
Debus, J.
Knoll, M.
Abdollahi, A.
RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1070 - S1071
[24] Sequence of Vessel Interruption in VATs Lobectomy for Early-Stage NSCLC
Li, Yun
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S769 - S769
[25] ILK STATUS AND THE PROGRESSION OF EARLY-STAGE NSCLC: A PILOT STUDY
Watzka, S. B.
Poetsch, I.
Marcher, M.
Setinek, U.
Weigel, G.
Mueller, M. R.
LUNG CANCER, 2009, 64 : S47 - S47
[26] SBRT for early-stage NSCLC: The predominant failure pattern is distant
Bradley, J. D.
El Naqa, I.
Trovo, M.
Parikh, P.
Drzymala, R. E.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S37 - S38
[27] Racial Disparities in Early-Stage NSCLC Treatment: A Call for Action
Pellini, Bruna
Chaudhuri, Aadel A.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (06) : 769 - 770
[28] Complete disappearance of an esophagogastric polyp with concurrent early-stage adenocarcinoma after administration of a proton pump inhibitor
Yoshida, T.
Shimizu, Y.
Hirota, J.
Ono, Y.
Nakagawa, M.
Ono, S.
Nakagawa, S.
Kato, M.
Asaka, M.
ENDOSCOPY, 2010, 42 : E176 - E177
[29] PARP inhibition in homologous-recombination-deficient early-stage breast cancer
Pusztai, L.
ANNALS OF ONCOLOGY, 2021, 32 (01) : 4 - 5
[30] Chemotherapy and Immunotherapy in Early-Stage NSCLC: Neoadjuvant vs Adjuvant Therapy
Wakelee, Heather
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (12) : 648 - 651

← 1 2 3 4 5 →